In This Article:
-
Revenue Growth: Approximately 40% increase in revenues over the past 12 months.
-
Net Product Sales (Q4 2024): $7.9 million, with a quarterly growth rate of approximately 13%.
-
Net Product Sales (Full Year 2024): $29.6 million, compared to $21.3 million in 2023.
-
Cash Burn (Q4 2024): Approximately $0.6 million.
-
Selling and Marketing Expenses (Q4 2024): $3.9 million, compared to $4.6 million in Q3 2024.
-
Selling and Marketing Expenses (Full Year 2024): $18.4 million, compared to $12.1 million in 2023.
-
G&A Expenses (Q4 2024): Decreased by $2.9 million compared to Q3 2024.
-
G&A Expenses (Full Year 2024): Increased by $2.4 million compared to 2023.
-
Cash and Cash Equivalents (End of 2024): $26.6 million.
-
Debt Repayment: Early partial repayment of $13 million of the $32 million outstanding convertible debt.
-
Cash Operating Expenses (Full Year 2024): Approximately $33 million, including $8 million related to European pre-commercialization and Norgine transaction expenses.
Release Date: March 10, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Fennec Pharmaceuticals Inc (NASDAQ:FENC) reported a 40% increase in revenues over the past 12 months, demonstrating strong financial growth.
-
The company successfully launched PEDMARK in major European markets, including Germany and the UK, expanding its international presence.
-
PEDMARK is gaining traction in major academic centers across the US, such as UCLA and Mount Sinai, validating its clinical utility.
-
Fennec Pharmaceuticals Inc (NASDAQ:FENC) has a strong cash position with $26.6 million in cash and cash equivalents as of December 31, 2024.
-
The company has made strategic hires in key management and commercial roles, strengthening its leadership team and expertise.
Negative Points
-
The company faces challenges in increasing awareness and adoption of PEDMARK among oncologists and the AYA population.
-
There is competition from compounded STS products, particularly in the pediatric market, which could impact PEDMARK's market share.
-
Fennec Pharmaceuticals Inc (NASDAQ:FENC) reported a cash burn of $0.6 million in the fourth quarter of 2024, indicating ongoing operational expenses.
-
The company anticipates similar cash operating expenses in 2025, which may impact profitability despite revenue growth.
-
There is uncertainty regarding the timing and outcome of regulatory and reimbursement approvals in international markets, such as Japan.
Q & A Highlights
Q: Did the pediatric business return to sequential growth in Q4, and what was the AYA contribution? A: Yes, the pediatric segment continued to grow, and the AYA segment has emerged as a significant opportunity. However, specific contributions from each segment were not disclosed. - Jeffrey Hackman, CEO